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Lysosomal proteolysisInducing tumor cell death is one of themajor therapeutic strategies in treating cancer. The aim of this study is to
investigate the mechanism underlying the involvement of autophagy in cell death induced by timosaponin AIII
(TAIII). Cell viability was determined by MTT and cologenic assay; apoptosis was determined by ﬂow cytometry
and TUNEL assay; autophagy was examined by immunoblotting and immunoﬂuorescence; ubiquitination was
detected by co-immunoprecipitation; mRNA expression was detected by real-time PCR; and determination of
necrotic cell death was approached with LDH assay. The in vivo tumor growth inhibition was determined by xe-
nograft model. TAIII exhibits potent cytotoxicity on human hepatocellular carcinoma (HCC) cells without severe
hepatic toxicity. TAIII induced caspase-dependent apoptosis in HCC, and the induction of apoptosis was attribut-
ed to the inhibition of TAIII on XIAP expression. Repressing XIAP expression allowed cell tolerance toward the
treatment with TAIII. The suppression of XIAP by TAIII is under post-transcriptional control and independent of
proteasomal-driven proteolysis. Instead, TAIII-induced AMPKα/mTOR-dependent autophagy was responsible
for XIAP suppression and triggered the XIAP heading lysosomal degradation pathway. Ubiquitination of IAPs is
required for the autophagic degradation induced by TAIII. Blockade of autophagy turns on the switch of necrotic
cell death in TAIII-treated cells. Timosaponin AIII induces HCC cell apoptosis through a p53-independent mech-
anism involving XIAP degradation through autophagy–lysosomal pathway. The possibility of developing TAIII as
a new anti-tumor agent is worth considering.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Successful exploration of paclitaxel, camptothecin and vincristine for
chemotherapy has revealed the potential of discovering novel chemo-
therapeutics from medical plants to combat human cancers. The
Chinese medicinal herb Anemarrhena asphodeloides Bunge (Fig. 1A)
has a long tradition of use in China to restrict tumor in cancer patients,
while a saponin component timosaponin AIII (TAIII) was identiﬁed to
be an active component. Previous studies of others and us revealed
the potential of TAIII as a potent anti-tumor agent in various human
cancers [1–3], while mechanisms mediating the anti-tumor effect of
TAIII remain unclear.
The inhibitors of apoptosis (IAPs) family members are well-known
endogenous inhibitors of caspase activities in HCC [4]. Overexpression
of IAP proteins was observed in HCC tissue allowing HCC cells to escapeSassoon Road, Pokfulam, Hong
t Ming Chemistry Building, The
na. Tel.: +852 28592154.
u.hk (C.-M. Che).
ights reserved.from apoptotic cell death [5]. In HCC patients, overexpression of XIAP,
the most identiﬁed IAP protein, was correlated with the increased risk
of relapse [6]. These studies deﬁne XIAP as an attractive target for HCC
therapy. Efforts on developingXIAP antagonistsweremade in the direc-
tion of designing small molecules to mimic the N-terminal end of active
secondmitochondria-derived activator of caspase (Smac) protein, ami-
tochondrial cytochrome C-dependent protein that antagonizes XIAP
activity and induces caspase activation [7]. The Smac and Smac-like pro-
teins bind to the IAPs and facilitate the auto-ubiquitination of IAPs,
which subsequently undergo rapid proteasomal degradation [8]. Recent
studies reveal thatmany ubiquitinatedmolecules are degraded through
selective autophagy–lysosomal pathways [9], however, whether the
strictly regulated XIAP could be engulfed by lysosome remains unclear.
In this study, we reported that autophagy-inductive TAIII exhibits
potent inhibitory effect on human hepatocellular carcinoma via induc-
ing caspase-dependent apoptosis to HCC cells. Less cytotoxicity of
TAIII was found in non-malignant cells. Initiation of apoptotic cell
death by TAIII depends on XIAP inhibition in HCC cells. TAIII could acti-
vate AMPKα signaling to suppress themTORpathway, which confers its
induction of autophagy. Induction of autophagy may be required for
XIAP suppression in TAIII-treated cells, which is demonstrated by the
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attenuate the inhibition of XIAP expression in HCC cells exposed to
TAIII. However, this was not observed when the TAIII-treated cells
were exposed to the proteasome inhibitor. Ubiquitination of XIAP pro-
tein is necessary for the degradation driven by autophagy–lysosomede-
pendent pathway. Blockade of autophagy by RNA interference against
Atg5 activates necrosis in TAIII-treated cells. Our study reveals that
using TAIII as a novel chemotherapeutic agent for hepatocellular carci-
noma should be worth considering.2. Results
2.1. TAIII potently suppresses tumor growth of hepatocellular carcinoma
Potent suppression of tumor growth and reduced cell viability could
be observed in HCC cell lines HepG2, MHCC97L, PLC/PRF/5 and Hep3B
(Fig. 1B) treated with TAIII from A. asphodeloides Bunge (Fig. 1A), in a
dose-dependent manner. The IC50 of TAIII varies within different cell
lines, however, no signiﬁcant relevance between the cytotoxicity of
TAIII and p53 status in HCC cell lines could be observed, which is indi-
cated by the phenomenon that TAIII may exhibit higher cytotoxicity to
p53-deﬁcient Hep3B cells than to p53-proﬁcient HepG2, MHCC97L
and PLC/PRF/5 cells. This may suggest that a p53-independent mecha-
nism may be involved in the induction of cell death by TAIII in HCC
cells. Clonogenic assay presents no signiﬁcant relapse nor resistance of
TAIII-treated HCC cells (Fig. S1). In addition, TAIII exhibits higher toxic-
ity to carcinoma cell lines than to normal hepatocytes (Fig. 1C), which
reveals that TAIII could exert its anti-tumor action in hepatocellular
carcinoma without inducing potent toxic effect in normal hepatocytes.
The toxicity of TAIII was monitored in vivo as well. In tumor bearing
nude mice generated by subcutaneous injection of MHCC97L, no re-
markable body weight loss could be observed (Fig. S2) in mice treated
with TAIII (7.5 mg/kg/2 days) while tumor growth was dramatically
restricted (Fig. 1D and S3). Ki67 expression, as a tumor proliferation
marker, was signiﬁcantly reduced in TAIII treated-xenograft (Fig. 1E).
These ﬁndings suggest that TAIII can be a worthy therapeutic agent for
HCC without inducing signiﬁcant toxic effect on normal hepatocytes.2.2. TAIII induces caspase-dependent apoptosis of hepatocellular
carcinoma cells
Previous study has reported that TAIII could initiate apoptosis in
Hela cancer cells [1], which confers the Hela cell death. The
apoptosis-inductive effect of TAIII could be further conﬁrmed in this
study from the observation that increased FITC-conjugated Annexin V
binds to the membrane phospholipid phosphatidylserine (PS) at the
outer leaﬂet of plasma membrane along with the PI permeability,
which indicates that HCC cells were undergoing apoptosis upon TAIII
intervention (Fig. S4). Activation of caspase cascade as well as PARP
cleavage further conﬁrms the apoptotic-inductive effect of TAIII in
HCC cells (Fig. 2A). To examine if the caspase-3 activation is responsi-
ble for the apoptosis induction, HCC cells were exposed to TAIII in the
presence of caspase inhibitor. Co-treatment with 50 μM Z-VAD-FMK
could signiﬁcantly ameliorate the cell death induced by TAIII treatment
in HCC cells, indicating that the apoptosis induction in TAIII-treated
cells may be attributed to the initiation of caspase activation
(Fig. 2B). Furthermore, TAIII could initiate apoptosis in xenografted
models. Intraperitoneal injection of TAIII (7.5 mg/kg/2 days) reduced
the size of the tumor in mice through the activation of tumor cell apo-
ptosis. This trait was depicted by DNA fragmentation, the hallmark of
apoptosis (Fig. 2C). Cleavage of caspase-3 and PARP could be observed
in xenografted tumor from mice with TAIII treatment (Fig. 2D). These
ﬁndings suggest that TAIII initiates caspase-dependent apoptosis in
HCC cells.2.3. TAIII is chemically similar to autophagy-inducers
By comparing the chemical ﬁngerprint of TAIII with those of target
sets in theWOBAT database, we carried out chemical similarity analysis
for TAIII. The top ranked target sets with compounds chemically similar
to TAIII are found to be “Na+/K+-ATPases” (E-value of 1.82E−13),
based on the pair-wise comparison of the chemical ﬁngerprint of
TAMIII with those of 225 ligands in the “Na+/K+-ATPases” target set.
“Na+/K+-ATPases”, such as cardiac glycosides, are known to induce au-
tophagy in human non-small cell lung cancer cells [PMID: 22750415]
and induce autolysosome formation and lysosomal degradation [PMID:
21635740]. Biochemical studies were performed to validate these
ﬁndings.
2.4. Induction of apoptosis by TAIII in hepatocellular carcinoma cells
requires inhibition of XIAP expression
It has been reported that knockdown of IAP genes by siRNA in-
duces apoptosis and suppresses proliferation in human cancer cells
[10]. The inductive effect of IAP suppression on apoptosis is p53-
independent, indicating that the p53 status does not affect the
grade of apoptosis induced [11]. Expression of XIAP was suppressed
upon TAIII treatment, however, it seems that in PLC/PRF/5 and
Hep3B cells, cIAP1 and cIAP2 could be suppressed while in HepG2
andMHCC97L cells, cIAP1 and cIAP2 could not respond to TAIII treat-
ment. However, TAIII treatment could effectively inhibit XIAP ex-
pression (Fig. S5). Considering that the cytotoxicity of TAIII in four
hepatocellular carcinoma cell lines is similar, this may indicate that
cIAP1 and cIAP2 may not be responsible as a main mechanism in
TAIII-induced apoptosis. To further prove this, we detected the
mRNA transcripts of cIAP1, cIAP2 and XIAP in non-malignant cell
line L-02 and HCC cell lines HepG2, MHCC97L, PLC/PRF/5 and
Hep3B. Interestingly, we found that only XIAP is aberrantly
expressed in malignant cell lines compared with non-malignant
cell line. The expression of cIAP1 and cIAP2 seems not speciﬁc with
regard to the malignancy of cell lines (Fig. S6). We found that the in-
hibition of TAIII on XIAP expression incurred in a dose- and time-
dependent manner (Fig. 3A), and the suppression of XIAP by TAIII
was in line with its cytotoxicity to HCC cells. However, it was ob-
served that TAIII could not suppress XIAP expression in non-
malignant L-02 cells. Inhibition of XIAP was observed in xenografted
tumor (Fig. 2D). Regarding the tolerance of non-malignant cell on
TAIII treatment, we may conclude that XIAP is majorly responsible
for the tumor suppressive effect of the compound. Furthermore,
when we knock-down the expression of cIAP1 and cIAP2 in HepG2
cells, the cytotoxicity effect of TAIII could not be dramatically affect-
ed (Fig. S7). To further examine if the inhibition of XIAP was respon-
sible for the cell death induced by TAIII in HCC cells, we introduced
RNA interference to suppress XIAP in HCC cells. Reduction of XIAP
expression could attenuate the cytotoxic effect of TAIII on HCC cells
(Fig. 3B), which indicated that TAIII mainly targeted on XIAP and
other IAP family member in inducing cytotoxic effect. Furthermore,
it could be observed that the grade of caspase activation was remark-
ably reduced in TAIII-treated HCC cells with XIAP silencing (Fig. 3C).
The reduced sensitivity of HCC cells with XIAP silencing toward the
TAIII treatment reveals that XIAP plays a major role in the TAIII-
induced apoptosis in hepatocellular carcinoma.
2.5. TAIII-induced AMPKα-activated autophagy in hepatocellular
carcinoma cells
Autophagy induction was observed in TAIII-treated HCC cells. The
increase of autophagosomal form of LC3 (LC3-II) along with the
decrease of cytoplasmic form of LC3 (LC3-I) reveals the initiation of
autophagy in TAIII-treated HCC cells (Fig. 4A). Consistent observa-
tion could be found in in vivo study (Fig. 2D). No signiﬁcant
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cells after 3 h TAIII-treatment (Fig. 4A). The induction of autophagy
by TAIII exposure was further conﬁrmed in HepG2 cells with a stable
expression of GFP-LC3. Elevated expression of autophagic punctatedots in TAIII-treated cells could be observed, which presented as
the indicative of autophagy when cells were exposed to TAIII
(Fig. 4B). Suppression of Atg5 expression by RNA interference signif-
icantly attenuated the formation of autophagic punctuation in TAIII-
2893N. Wang et al. / Biochimica et Biophysica Acta 1833 (2013) 2890–2899treated cells (Fig. 4B). Previous study has shown that TAIII is capable
of inhibiting mTOR signaling, the negative regulatory of autophagy,
in human cancer cells [2]. In our study, we found that AMPKα, one
of the upstream regulators of mTOR, was activated by TAIII treat-
ment in HCC cells. Activation of AMPKα may be responsible for the
autophagy induction by mTOR inhibition [12]. To further conﬁrm
the role of AMPKα in autophagy initiation in cells with TAIII inter-
vention, HCC cells were treated with TAIII in the presence of
AMPKα inhibitor Compound C. Inactivation of AMPKα in TAIII-
treated cells restored the mTOR activity and blocked the induction
of autophagy (Fig. 5A and B). TAIII exerts no signiﬁcant effect on
the activities of Akt and Erk signaling (Fig. 5B). In addition,
induction of autophagy in TAIII-treated HCC cells was attenuated
by the presence of AMPKα inhibitor Compound C (Fig. 5C). Recovery
of mTOR activity under AMPKα inhibition reveals the central role of
AMPKα in the regulation of autophagy in TAIII-treated HCC cells.
2.6. Suppression of XIAP expression by TAIII requires autoubiquitination and
autophagy induction
We tried to discriminate the role of autophagy in cell death induced
by TAIII in HCC cells. With RNA interference against Atg5, we blocked
the induction of autophagy in HCC cells exposed to TAIII. Interestingly,
we found that the expression of XIAP was restored by autophagy in-
hibition, which indicated the potential role of autophagy in the XIAP
suppression induced by TAIII treatment (Fig. 6A). To explore the under-
lyingmechanism involved in XIAP suppression, themRNA transcripts of
XIAP inHCC cells exposed to TAIIIwere detected. No potent reduction of
mRNA transcript level of XIAP was observed, which indicated that a
post-transcriptional regulation mechanism may be involved (Fig. S8).
We blocked the proteasomal degradation by pre-treating HCC cells
with protease inhibitor MG-132. However, the presence of MG-132 did
not attenuate the XIAP proteolysis induced by TAIII treatment. Interest-
ingly, we observed restoration of XIAP expression in TAIII-treated cells
in the presence of lysosome inhibitor leupeptin (Fig. 6B). Leupeptin is a
protease inhibitor that blocks the degradation of lysosome-engulfed pro-
teins. In addition, increasing ubiquitination of XIAP could be observed in
TAIII-treated HCC cells (Fig. 6C). This critical role of ubiquitination in IAP
protein lysosomal degradation was further conﬁrmed with the observa-
tion that presence of ubiquitin E1 enzyme inhibitor PYR-41 blocked the
degradation of XIAP in TAIII-treated cells (Fig. 6D). These ﬁndings sug-
gest a novel mechanism of XIAP degradation involving ubiquitination-
dependent autophagic proteolysis.
2.7. Inhibition of autophagy in TAIII-treated cells initiates necrotic cell death
To determine the role of autophagy in TAIII-induced HCC cell death,
we blocked the autophagy induction in TAIII-treated cells with RNA in-
terference against Atg5. Increased cytotoxicity was observed in TAIII-
treated cells when autophagy was suppressed (Fig. 7A). Further deter-
mination of death mode in autophagy-suppressed HCC cells with TAIII
exposure was conducted, and the membrane permeability of PI after
3 h treatment of TAIII was signiﬁcantly increased in hepatoma cells
which autophagy was suppressed, indicating that a quick loss of mem-
brane integrity and induction of necrosis occur in TAIII-treated HCC
cells once autophagy is inhibited (Fig. 7B). Initiation of necrosis
by TAIII in autophagy-suppressed cells was further conﬁrmed with
examining the release of LDH, which was the biomarker of necrotic cellFig. 1. The proﬁle of TAIII and anti-tumor effect of TAIII in hepatocellular carcinoma. A shows ori
left. B shows the cytotoxicity of TAIII in different hepatocellular carcinoma cells. Cell viability w
exhibited not as potent cytotoxicity to HCC cells as to normal cells. Human normal hepatocyt
D shows TAIII suppressed tumor growth in xenograft model. Nude mice were subcutaneously
mice were grouped randomly and treated with either PBS or TAIII (5 mg/kg/2 days) intrap
**p b 0.01 when compared with PBS treatment group. E shows that tumor proliferation marke
out and sectioned. The tissuewas then stainedwith Ki67 antibody (red) and DAPI (blue), and im
could be observed. The tumor marker Ki67 was suppressed by TAIII treatment.death. Potent increase of LDH activity in culture medium was found in
autophagy-suppressed HCC cells, which indicated that cells with au-
tophagy inhibitionmay undergo necrotic cell death upon TAIII treatment
(Fig. 7C). Our data suggests that autophagy is necessary for the induction
of apoptosis in TAIII-treated hepatocellular carcinoma cells.
3. Discussions
Autophagy is deﬁned as a biological process that the cell consumes
its' own cellular components through the lysosome machinery [13].
It is a homeostatic process that preserves to maintain the balance
between synthesis, degradation and subsequent recycling of cellular
components [14]. As a well recognized process, autophagy is now
regarded as complicated genetic cascades that at least three distinct
forms of autophagy were identiﬁed with different cellular and molecu-
lar machineries, macroautophagy, microautophagy (mitophagy) and
chaperone-mediated autophagy (CMA) [15]. In chaperone-mediated
autophagy, the autophagic vacuoles only recognize the particular pro-
teins tagged with chaperones and deliver the selected molecules to
the lysosome for proteolysis process [16]. In our study, we observed
that the cellular endogenous inhibitors of apoptosis XIAP could undergo
selective autophagy induced proteolysis. The protein degradation in-
duced by TAIII in HCC cells is independent of proteasome but relies on
lysosomal pathway. The XIAP was previously reported to be degraded
through proteasomal degradation [17] and our study concludes that
the selective autophagy-signaling may be the complementary ma-
chinery for regulating its expression. In addition,we found that thepro-
tein degradation of XIAP induced by TAIII requires ubiquitination of the
XIAP. Proteosomal degradation of XIAP also requires ubiquitin labeling
onto the protein. However, the XIAP degradation by autophagy is an ac-
tion different from our knowledge that XIAP could be majorly degraded
through proteosome pathway. The switch directing the protein to
either proteasomal degradation or autophagy–lysosomal degrada-
tion pathway is still incompletely unveiled. However, it is known
that ubiquitination process of the targeted proteins connects the two
complementary but strictly separated pathways [18]. Previous study
has found that autophagy could be a compensation mechanism to
degrade proteins when the ubiquitin–proteosomal system (UPS) is
impaired [19]. In our study we could not observe the recruitment of
RING, the E3 ligase of XIAP, even though XIAP is ubiquitinated in TAIII-
treated cells (data not shown). This may indicate that proteosomal
degradation of XIAP is impaired in TAIII-treated HCC cells. The exact
mechanism is still undergoing investigation.
The relationship between apoptosis and autophagy in mammalian
cells is complicated in the sense that, under some circumstances, au-
tophagy may be either a negative or positive regulator in inducing
apoptosis when it occurs spontaneously with apoptosis [20]. The com-
plex interplay between autophagy andapoptosis requires a thorough in-
vestigation in each particular case. Currently, it is the common concept
that autophagy plays a role in deciding cell fate in a given cell, but it pri-
marily depends on the types and degrees of death stimuli or stress fac-
tors which the cell is exposed to [21]. In our study, we identiﬁed a
new relationship between apoptosis and autophagy in TAIII-treated
HCC cells. Autophagy started prior to apoptosis initiation to degrade
the endogenous apoptosis inhibitor XIAP through lysosome-dependent
pathway. The degradation of apoptosis suppressor facilitates the activa-
tion of alternative apoptosis pathway. It could be therefore concluded
that the apoptosis in TAIII-treated HCC cells depends on autophagicginal plant of Anemarrhena asphodeloides Bunge on right and chemical structure of TAIII on
ith treatment of TAIII for 24 h and 48 h was determined by MTT assay. C shows that TAIII
es were treated with TAIII for 24 h then the cell viability was determined by MTT assay.
injected with 5 × 107 MHCC97L cells to allow tumor growth. One week after injection,
eritoneally for 3 weeks. Measurement of tumor size was conducted once per 2 days.
r Ki67 was suppressed in TAIII-treated mice. At the end of the study, tumor was dissected
ageswere captured. The left panel shows that signiﬁcant inhibition on tumor size by TAIII
Fig. 2. TAIII induces apoptosis in hepatocellular carcinoma. A shows caspase-cascade activation by TAIII in hepatocellular carcinoma cells. Cells with TAIII intervention were lysed and related target proteins were detected by immunoblotting with
speciﬁc antibodies. Results indicated that 24 h treatment of TAIII induced dose-dependent caspase-3 (pro-form 32 kDa, cleaved form 17 kDa) and PARP (pro-form 112 kDa, cleaved form 89 kDa) cleavage in hepatocellular carcinoma cells. B shows
the presence of 50 μM caspase inhibitor Z-VAD-FMK attenuated apoptosis induced by TAIII. Cells were treated with TAIII in the presence and absence of 50 μM Z-VAD-FMK for 24 h. Cell viability was determined by MTT assay. Δp b 0.05 and
ΔΔp b 0.01 when compared with control. C shows TAIII induced apoptotic cell death in vivo. The xenograft model was established as indicated in Fig. 1D and the tumor was ﬁxed and the parafﬁn section was prepared. Apoptotic tumor cells
were stained with TUNEL assay kit. D shows that TAIII could induce differential protein expressions in xenografted tumor. The collected tumor was homogenized and protein was collected. Expression of LC3, XIAP, caspase-3 and PARP was detected
by immunoblotting. Decreased expression of XIAP and increased cleavage of caspase-3 and PARP by TAIII were observed. Increase of membrane form of LC3 (LC3-II) with decreased cytosolic form LC3-I was found.
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Fig. 3. Suppression of XIAP expression by TAIII in hepatocellular carcinoma cells confers induction of caspase-dependent apoptosis. A shows that the expression of XIAPwas suppressed by
TAIII treatment in hepatocellular carcinoma cells. Cells with TAIII interventionwere lysed and XIAP expressionwas determined by immunoblotting. Dose- and time-dependentmanner of
XIAP inhibition by TAIII intervention was observed. B shows the silencing of XIAP in hepatocellular carcinoma by RNA interference reduced cell sensitivity to TAIII intervention. Cells were
transiently transfected with siRNA against XIAP followed by TAIII intervention for 24 h. Cell viability was analyzed byMTT assay. Δp b 0.05 and ΔΔp b 0.01 when comparison was made
between treatment with TAIII combined with scramble negative control (scr) siRNA and treatment with TAIII combined with siRNA against XIAP. C shows that activation of caspases by
TAIII was attenuatedwith RNA interference of XIAP. Expression of XIAPwas suppressed with RNA interference and then cells were treatedwith TAIII for 24 h. Activation of caspase-3 and
PARP was detected by immunoblotting.
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presented that autophagy-dependent protein degradation induced by
TAIII requests conjugation of poly-ubiquitin to the protein, which leads
to the degradation of those particular molecules by lysosome pathway
[22]. Here we suggest that ubiquitinated XIAP is degraded through this
autophagy-dependent proteolysis pathway leading to induction of apo-
ptosis to HCC cells. It was previously shown that induction of autophagy
is required for apoptosis induction in CR4/CXR4-expressing T cells
interacting with HIV-1-encode envelope glycoproteins [23], and au-
tophagy induced by anti-tumor agent promotes the apoptotic death in
cancer cells [24]. Our study suggests that XIAP can be the mediators in
autophagy-related apoptosis initiation.
We noticed that inhibition of autophagy did not attenuate cell death,
which was controversial with our expectation since the apoptotic cell
death induced by TAIII required the participation of autophagy. By
contrast, exacerbated cell death was observed. Further study showed
that inhibition of autophagy switched on necrosis in TAIII-treated HCC
cells. The switch between apoptosis and necrosis is not completelyrevealed, but it was observed that primary cultured cortical neurons un-
dergo necrosis in low-density culture while they initiate apoptosis at
high density [25], which is mediated by the necrosis-inhibitory mole-
cules prothymosinα [26]. Previous study also showed that induction
of autophagy in chemotherapy-injury liver impairs necrosis, which pro-
vokes inﬂammation-related damage of hepatocytes, which reveals the
role of autophagy in maintaining cell to undergo apoptotic death [28].
Depletion of LAMP2 which impaired selective autophagy is reported
to initiate a switch from apoptosis to necrosis [27], but the involvement
of related molecules has not been unveiled. Our study shows that XIAP
may be capable in mediating a switch from apoptosis to necrosis. A
systemic scheme on the regulatory network of TAIII-induced cell
death was shown in Fig. S9.
In conclusion, a novel mechanism involved in XIAP-induced apopto-
sis was reported in HCC cells exposed to TAIII. TAIII was found cytotoxic
to HCC cells independent of p53 status, and in vivo tumor growth of
hepatocellular carcinoma cells could be suppressed by TAIII treatment.
TAIII exhibits less toxicity to non-malignant cells. TAII-induced caspase-
Fig. 4. TAIII induces autophagy in hepatocellular carcinoma cells. A shows immunoblotting of LC3, the autophagy marker in hepatocellular carcinoma cells with TAIII intervention. Cells
were treatedwith TAIII as indicated and proteinwas collected for immunoblotting. Signiﬁcant increase of LC3-II (membrane form)with decrease of LC3-I (cytoplasmic form)was observed
and indicated induction of autophagy by TAIII. B shows increase of autophagic ﬂux by TAIII intervention in HepG2 cells stably expressing GFP-LC3. RNA interference against Atg5 remark-
ably blocked autophagicﬂux induced by TAIII.Δp b 0.05 andΔΔp b 0.01when comparisonwasmade between treatmentwith TAIII combinedwith scramble negative control (scr) siRNA
and treatment with TAIII combined with siRNA against Atg5.
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tion on XIAP expression. TAIII did not reduce the mRNA transcripts of
XIAP, and inhibition of proteasome did not restore the XIAP level in
TAIII-treated cells. Instead, TAIII induced AMPKα/mTOR-dependent se-
lective autophagy which brought the XIAP protein to lysosomal degra-
dation pathway. The autophagy-related lysosomal degradation of XIAP
required its ubiquitination. Blockade of autophagy accelerated the cyto-
toxic effect of TAIII in HCC cells, whichwas attributed to the activation of
necrotic cell death in autophagy-suppressed HCC cells exposed to TAIII.
Our study reveals the potential of TAIII as a potential therapeutic drug
candidate against HCC with novel mechanism involved.4. Materials and methods
4.1. Cell lines and cell culture
The human hepatocellular carcinoma cell lines HepG2, PLC/PRF/5 and
Hep3B were purchased from ATCC (USA); MHCC97L cell line was kindly
gifted by Dr. Man Kwan from the Department of Surgery, The University
of Hong Kong. The human normal hepatic cell line L-02 was purchased
from the Laboratory Animal Center in Sun Yat-Sen University (Guang-
zhou, P.R. China). All cell lines were cultured in Dulbecco's modiﬁed
Eagle's medium (DMEM, with high glucose, Life Technologies, USA)
supplementedwith 10% fetal bovine serum(FBS) and 1%penicillin/strep-
tomycin (Life Technologies, USA). Cells were incubated in a
humidiﬁed atmosphere containing 5% CO2 at 37 °C.4.2. Calculation of autophagic ﬂux
Induction of autophagy was measured by calculating the autophagic
ﬂux in cells with treatment. In brief, HepG2 cells were transfected with
plasmids encoding GFP-LC3 (kindly gifted by Prof. Tamotsu Yoshimori,
Osaka University, Japan) and cells with GFP-LC3 stable expression were
selected. Tomeasure the autophagic ﬂux, cells with treatment were visu-
alized underﬂuorescencemicroscope (Carl Ziess, USA, 40×, CCD camera).
Three scopes of each treatment were captured and the FITC-positive au-
tophagic punctate dots were counted. Increased number of autophagic
puncta indicated the induction of autophagic ﬂux upon treatment.4.3. Co-immunoprecipitation assay
The ubiquitination of XIAPwas determined by co-immunoprecipita-
tion assay with Pureproteome Protein G Magnetic Beads (Millipore,
USA) according to the instruction provided by the manufacturer. In
brief, cells were treated with timosaponin AIII in the presence of
leupeptin for 6 h. Then cells were collected and lysed with NP-40 lysis
buffer (Invitrogen, USA) supplemented with cocktail protease inhibitor
(Roche, USA), and 50 μl of cell lysates was collected for input control.
The ubiquitinated XIAP was precipitated by binding to magnetic beads
pre-incubated with XIAP antibody. The ubiquitinated XIAP was then
eluted with 0.2 M glycine (pH 2.5) after washing thoroughly. Eluted
protein wasmixed with loading buffer and heat at 90 °C Ubiquitination
of XIAP was detected by immunoblotting with antibody against
Fig. 5.Activation of AMPKα is responsible for autophagy induction by TAIII. A shows that TAIII-activated AMPKαwas responsible for the autophagy induction in hepatocellular carcinoma
cells. Potent activation of AMPKα was observed in cells with TAIII intervention along with autophagy induction. Suppression of mTOR signaling and its substrates S6K and S6 was also
observed. B shows that inhibition of AMPKα by pre-treatment of Compound C (20 μM) prevented the inhibition of mTOR and its substrates by TAIII and suppressed autophagy induction
in hepatocellular carcinoma cells. TAIII exhibits no effect on other upstreamed signaling of mTOR such as Akt and Erk1/2 after 24 h treatment. C shows that inhibition of AMPKα by pre-
treatment of Compound C (20 μM) attenuated the induction of autophagy in TAIII-treated HCC cells. *p b 0.05, **p b 0.01 when compared with non-treated cells; Δp b 0.05 and
ΔΔp b 0.01 when comparison was made between treatment with TAIII alone and treatment with TAIII combined with Compound C.
2897N. Wang et al. / Biochimica et Biophysica Acta 1833 (2013) 2890–2899ubiquitin. Expression of XIAP in puriﬁed protein and input lysate was
detected with antibody against XIAP as loading control.
4.4. Xenograft model
The in vivo anti-tumor activity of TAIII was examined by xenograft
model. In brief, female nude mice subcutaneously received 1 × 107
MHCC97L cells on its right ﬂank. One week after injection, mice were
randomized into two groups. One of which received 7.5 mg/kg TAIII
three times per week through intraperitoneal injection for 3 weeks
while the other received PBS. Tumor growth and body weight were
monitored three times per week. At the end of the study, the mice
were sacriﬁced with overdose of phenobarbital (200 mg/kg). Tumor
was dissected out and subjected to histological analysis. All animal pro-
tocols have been approved by the Committee on theUse of Live Animals
in Teaching and Research (CULATR), The University of Hong Kong and
complied with international ethical requirement in animal study.
4.5. Chemical similarity analysis
A chemical similarity approach (SEA)was recently developed to pre-
dict targets for new drugs [PMID: 19881490]. In brief, SEA is a databaseof a large number of compounds, whose biological targets are known.
These reference compounds are classiﬁed according to their biological
targets and named as “target sets”. Using a statistical model, the chem-
ical similarity between TAIII and all the compounds in each target sets
were computed and ranked.
4.6. Statistical analysis
Statistical analysis was conducted using Student's t-test.
Other supporting information on materials and methods was
presented in Supplemental document.
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